Compare SHAK & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAK | DNLI |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2014 | 2017 |
| Metric | SHAK | DNLI |
|---|---|---|
| Price | $97.14 | $19.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $116.74 | $34.33 |
| AVG Volume (30 Days) | 996.4K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 354.17 | N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,445,306,000.00 | N/A |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $15.07 | $408.85 |
| P/E Ratio | $91.31 | ★ N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $76.51 | $12.58 |
| 52 Week High | $142.23 | $23.77 |
| Indicator | SHAK | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 45.02 |
| Support Level | $85.64 | $18.42 |
| Resistance Level | $107.47 | $20.71 |
| Average True Range (ATR) | 3.70 | 0.95 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 48.47 | 17.50 |
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine, and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh-brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water. Geographically, the company generates the majority of its revenue from the United States.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.